Treatment
Immune checkpoint inhibitor clinical trials
We’re tracking 177 recruiting studies that include Immune checkpoint inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT06562777Recruiting
How symptoms differ between men and women during immunotherapy
This study looks at how symptoms during immunotherapy (a cancer treatment that boosts your immune system) may differ between men and women. Researchers will follow people with cancer who are starting immunotherapy to see if men and women report different side effects.
Portland, OregonAges 18 years+ - NCT06279104Recruiting
Comparing treatments for ovarian clear cell carcinoma
This study compares different ways to treat ovarian clear cell carcinoma, a rare type of ovarian cancer. It is for women whose cancer has come back or not gone away after platinum chemotherapy, or those newly diagnosed.
Wuhan, HubeiAges 18–75 - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT04891016RecruitingPhase 2
Immunotherapy with chemotherapy for locally advanced stomach cancer
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Zhengzhou, HenanAges 18–70 - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Anchorage, AlaskaAges 18 years+ - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05053802RecruitingPhase 2
Microwave tumor ablation plus immunotherapy for multiple lung cancers
This Phase 2 trial studies whether combining microwave ablation (a procedure to destroy lung tumors) with an immune checkpoint inhibitor can control multiple early lung cancers safely. It also aims to see how well the immune treatment helps after ablation, in people whose cancers have not spread.
Shanghai, Shanghai MunicipalityAges 18–79 - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT07216495Recruiting
Exercise study for early-stage triple-negative breast cancer patients
This study tests if aerobic exercise can help women and men with stage 2 or 3 triple-negative breast cancer who are getting chemotherapy and immunotherapy before surgery. It aims to see if exercise improves treatment outcomes and quality of life.
Houston, TexasAges 18 years+ - NCT05745233Enrolling by invitation
Testing immune therapy put into the belly for cancer fluid
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
Taichung, Please SelectAges 20 years+ - NCT06132698RecruitingPhase 2
Immunotherapy injected into spinal fluid for lung cancer that has spread to the brain lining
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
Chengdu, SichuanAges 18–75 - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT07705438Recruiting
PET scan to predict if immunotherapy works in TNBC
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
ShanghaiAges 18 years+ - NCT07689643RecruitingEarly Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Wuhan, HubeiAges 18 years+ - NCT04038619RecruitingPhase 1
Fecal transplant for immune-therapy diarrhea or bowel inflammation
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Houston, TexasAges 18 years+ - NCT04572451RecruitingPhase 1
Radiation with two antibody drugs for advanced, metastatic cancers
This early-phase trial tests whether a focused type of radiation (SBRT) given with anti–PD-1 and an anti–IL-8 antibody is safe in people with advanced cancers that have spread. It also looks for whether this combination might help control tumors at a few treatable spots.
Chicago, IllinoisAges 18 years+ - NCT04615988Recruiting
Vitamin D levels and hormone side effects from immune cancer therapy
This study looks at whether your blood vitamin D level is linked to hormone-related side effects caused by immune checkpoint cancer drugs. It may help doctors better predict who is at risk and how to monitor patients during treatment.
New York, New YorkAges 18 years+ - NCT04624399RecruitingPhase 2
Atezolizumab before bladder or kidney-tract surgery
This trial tests atezolizumab (an immune therapy) given before surgery for certain bladder or upper urinary tract cancers. The goal is to shrink or control the cancer early and improve outcomes after curative surgery.
LondonAges 18–99 - NCT04751396Recruiting
Melanoma education for people with autoimmune conditions
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Houston, TexasAges 18 years+ - NCT04766515Recruiting
Study of immune checkpoint cancer treatment in real life
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
ShanghaiAges 18 years+ - NCT04892849Recruiting
PD-1/PD-L1 immunotherapy plus radiation for solid tumors
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Erlangen, BavariaAges 18 years+ - NCT04902846Recruiting
Checking kidney side effects from immune cancer medicines
This study looks at how immune checkpoint medicines (sometimes combined with other treatments like chemotherapy) may affect the kidneys. It may help doctors better prevent or manage kidney side effects in people starting these therapies.
SalamancaAges 18–100 - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT04954599RecruitingPhase 1/Phase 2
CP-506 for hard-to-treat cancers with DNA repair defects
This Phase 1/2 study tests CP-506 in people with advanced solid tumors that have specific DNA repair problems (homologous recombination or Fanconi anemia-related defects). It may be used alone or combined with carboplatin or an immune therapy, aiming to shrink tumors or improve control when standard options are limited.
BrusselsAges 18 years+
Common questions
- Are there clinical trials studying Immune checkpoint inhibitor?
- Yes. Clin2 currently lists 177 recruiting studies that include Immune checkpoint inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Immune checkpoint inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Immune checkpoint inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Immune checkpoint inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.